Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas and virtually.
The presentation details are as follows:
- Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC
- Abstract Number: 765
- Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
- Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
- Location: George R. Brown Convention Center -Level 1 -Exhibit Halls AB
Xenetic Biosciences (NASDAQ:XBIO) ha annunciato che il suo abstract è stato accettato per una presentazione poster alla 39a Riunione Annuale della Society for Immunotherapy of Cancer (SITC). L'evento si svolgerà dal 6 al 10 novembre 2024, a Houston, Texas e virtualmente.
Dettagli della presentazione sono i seguenti:
- Titolo: Il targeting della DNase I per le trappole extracellulari dei neutrofili migliora il blocco del checkpoint immunitario CTLA-4 in modelli di CRC MSS/MMRp
- Numero dell'Abstract: 765
- Presentatore: Reid Bissonnette, Ph.D., Consulente Esecutivo per la Ricerca e Sviluppo Traslazionale presso Xenetic
- Data e Ora: Venerdì, 8 novembre 2024, dalle 9:00 alle 19:00 CST
- Luogo: George R. Brown Convention Center - Livello 1 - Sale Espositive AB
Xenetic Biosciences (NASDAQ:XBIO) anunció que su resumen ha sido aceptado para una presentación de póster en la 39ª Reunión Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC). El evento se llevará a cabo del 6 al 10 de noviembre de 2024, en Houston, Texas y de forma virtual.
Los detalles de la presentación son los siguientes:
- Título: El direccionamiento de DNase I de trampas extracelulares de neutrófilos mejora el bloqueo del punto de control inmunológico CTLA-4 en modelos de CRC MSS/MMRp
- Número del Resumen: 765
- Presentador: Reid Bissonnette, Ph.D., Consultor Ejecutivo de Investigación Translacional y Desarrollo en Xenetic
- Fecha y Hora: Viernes, 8 de noviembre de 2024, de 9:00 a.m. a 7:00 p.m. CST
- Ubicación: Centro de Convenciones George R. Brown - Nivel 1 - Salas de Exposición AB
Xenetic Biosciences (NASDAQ:XBIO)는 자사의 초록이 제39회 미국 암 면역 치료학회(SITC) 연례 회의에서 포스터 발표로 수락되었다고 발표했습니다. 이 행사는 2024년 11월 6일부터 10일까지 텍사스 주 휴스턴에서 진행되며, 온라인으로도 개최됩니다.
발표 세부 사항은 다음과 같습니다:
- 제목: DNase I이 중성구Extracellular trap을 겨냥하여 MSS/MMRp CRC 모델에서 CTLA-4 면역 체크포인트 차단을 개선하다
- 초록 번호: 765
- 발표자: Reid Bissonnette, Ph.D., Xenetic의 번역 연구 및 개발에 대한 고위 컨설턴트
- 날짜 및 시간: 2024년 11월 8일 금요일, 오전 9시부터 오후 7시까지 CST
- 장소: 조지 R. 브라운 컨벤션 센터 - 1층 - 전시 홀 AB
Xenetic Biosciences (NASDAQ:XBIO) a annoncé que son résumé a été accepté pour une présentation par affiche lors de la 39e Réunion Annuelle de la Society for Immunotherapy of Cancer (SITC). L'événement se déroulera du 6 au 10 novembre 2024 à Houston, Texas, et virtuellement.
Les détails de la présentation sont les suivants :
- Titre : Ciblage de la DNase I des pièges extracellulaires des neutrophiles pour améliorer le blocage des points de contrôle immunitaires CTLA-4 dans des modèles de CRC MSS/MMRp
- Numéro de résumé : 765
- Présentateur : Reid Bissonnette, Ph.D., Consultant Exécutif pour la Recherche et le Développement Translationnels chez Xenetic
- Date et Heure : Vendredi 8 novembre 2024, de 9h00 à 19h00 CST
- Lieu : Centre de conventions George R. Brown - Niveau 1 - Salles d'exposition AB
Xenetic Biosciences (NASDAQ:XBIO) gab bekannt, dass sein Abstract für eine Posterpräsentation bei der 39. Jahrestagung der Society for Immunotherapy of Cancer (SITC) akzeptiert wurde. Die Veranstaltung findet vom 6. bis 10. November 2024 in Houston, Texas, und virtuell statt.
Die Präsentationsdetails sind wie folgt:
- Titel: DNase I-Targeting von neutrophilen extrazellulären Fallen verbessert die CTLA-4-Immuncheckpoint-Blockade in Modellen von MSS/MMRp CRC
- Abstract-Nummer: 765
- Referent: Reid Bissonnette, Ph.D., Executiver Berater für Translationale Forschung und Entwicklung bei Xenetic
- Datum und Uhrzeit: Freitag, 8. November 2024, 9:00 - 19:00 Uhr CST
- Ort: George R. Brown Convention Center - Ebene 1 - Ausstellungsräume AB
- Abstract accepted for poster presentation at a major oncology conference (SITC)
- Opportunity to showcase research on DNase I targeting and immune checkpoint blockade
- None.
FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually.
Details of the presentation are as follows:
Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC
Abstract Number: 765
Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
Location: George R. Brown Convention Center -Level 1 -Exhibit Halls AB
For more information about the conference, visit www.sitcancer.org/2024.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on accesswire.com
FAQ
When and where will Xenetic Biosciences (XBIO) present its research at SITC 2024?
What is the title of Xenetic Biosciences' (XBIO) abstract for SITC 2024?
Who will be presenting Xenetic Biosciences' (XBIO) research at SITC 2024?
